BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Angle PLC Release: Parsortix, Inc. Granted US Patent


8/23/2011 9:40:35 AM

August 23, 2011 -- ANGLE plc (AIM : AGL) is delighted to announce that Parsortix Inc (“Parsortix”), its 83% owned portfolio company which specialises in medical diagnostics has been issued a U.S. Patent Number 7,993,908, entitled “Microstructure for Particle and Cell Separation, Identification, Sorting, and Manipulation”.

This patent is the first in what is expected to be a series of United States and International patents for Parsortix’s proprietary devices and methods for isolating cells from blood and other mixed cell suspensions. The proprietary devices and methods can be used for a wide range of medical diagnostic applications including, for example, the isolation of disseminated or circulating tumour cells from cancer patient samples and the capture of a developing foetus’ cells from a sample of its mother’s peripheral blood.

Using Parsortix’s now-patented technology, cells can be differentiated from one another based on their size, shape, deformability, or a combination of these characteristics. Unlike many cell-separating technologies that rely on antibody binding, the Parsortix technology does not require target cells to express and display antibody-binding protein for separation and, as a result, substantially reduces problems sometimes associated with that approach such as the risk of false positives or false negatives.

In addition to capturing rare cells in a population, the Parsortix technology enables further identification or characterisation through molecular or biochemical analysis.

Parsortix Chief Executive, Dr. Shane Booth, commented:

“Parsortix’s technology represents a new platform upon which identification and isolation of rare cells from mixed populations can be performed. Award of this patent substantiates our technological and consequent commercial capability and will be the basis of product development activity with which we intend to solve significant barriers to clinical and research capability.”

ANGLE Founder and Chief Executive, Andrew Newland, commented:

“This is a major step forward for ANGLE’s development of Parsortix. The validation of the Parsortix’s capability to successfully isolate cancer cells in blood is on track. We continue to be greatly encouraged by ongoing progress and look forward to reporting positive results in due course.”

For further information:

ANGLE plc 01483 685830

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

Collins Stewart Europe Limited

Matt Goode

0207 523 8350

Buchanan

Lisa Baderoon, Catherine Breen

020 7466 5000

Scott Harris

Stephen Scott, James O'Shaughnessy, Harry Dee 0207 653 0030


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->